

Today's issue of PD

Pharmacy Daily today features two pages of news.

Have your say

THE Pharmaceutical Society of Australia (PSA) has launched its national consultation for the review and update of the clinical governance principles for pharmacy services.

Pharmacists are invited to have their say on the framework, which will be critical to supporting safe, consistent and high-quality care - see the principles [HERE](#).

"Clinical governance is fundamental in delivering safe and effective person-centred pharmacy care," PSA national president, Professor Mark Naunton, said.

"Strong clinical governance underpins patient safety, and patients should be confident that they will receive high-quality care wherever they access pharmacy services."

Pharmacists can submit their feedback [HERE](#) before 10 Sep or opt for a one-on-one virtual consultation with the project manager, which can be booked by emailing Mirna.Sydenham@psa.org.au.

Chemist Warehouse has Gotcha4Life

CHEMIST Warehouse has raised a record-breaking \$1.5 million in support of national mental fitness charity, Gotcha4Life, through its 2026 Men's Health campaign, which kicked off on 10 Jun.

Funds were raised through customer donations in Chemist Warehouse stores nationwide, sale of Gotcha4Life men's care boxes, and 5% of sales from selected partner brands donated throughout the campaign period.

The money will help the organisation deliver preventative programs in schools, sporting clubs, workplaces and communities across Australia, giving people the skills, confidence and connections



to build their mental fitness throughout life.

"At Chemist Warehouse, we believe everyone should have access to the support they need to improve their health and wellbeing, and that's exactly what Gotcha4Life is helping to achieve through its focus on building mental fitness," Chemist Warehouse deputy CEO Mario Tascone said.

4 ways to help build strong bones



Petrus
PHARMACEUTICALS

Available from Symbion, Sigma, API & CH2

Always read the label and follow the directions for use.

Groundbreaking T1D drug hits PBS hurdle


THE Pharmaceutical Benefits Advisory Committee (PBAC) has declined to recommend PBS listing of Tzield (teplizumab), just months after the Therapeutic Goods Administration (TGA) approved the treatment as Australia's first non-insulin therapy shown to delay the onset of symptomatic type 1 diabetes (T1D) (*PD* 27 May).

Tzield, manufactured by Sanofi, is an immunotherapy given to adults and children aged eight years and older with stage two T1D, with the aim of delaying progression to symptomatic, stage three disease.

While PBAC accepted that the biologic therapy delays progression from stage two to stage three T1D, it was not satisfied with the certainty around the longer-term clinical benefits and cost-effectiveness at the proposed price.

During its Jul meeting, the committee also raised concerns about the proposed approach to identifying eligible patients, noting that screening relatives of people with T1D would not provide equitable access because most people diagnosed with T1D do not have a family history.

"The PBAC considered a coordinated approach to diagnosing Stage 2 T1D would be important to ensure equitable early



diagnosis and access to potential treatments such as teplizumab," the committee wrote in its Jul recommendations, released on Fri.

Sanofi said it was "disappointed by the PBAC's decision", adding it was "committed to working with all stakeholders to resubmit teplizumab again for funding consideration at the earliest opportunity".

MEANWHILE, PBAC also declined to recommend expanding PBS access to Dupixent (dupilumab,

Sanofi) for children aged six months to 11 years with chronic severe atopic dermatitis.

Despite acknowledging the significant clinical need for effective treatment in children with the condition, the committee said it considered the proposed price of dupilumab too high to support a cost-effective listing, noting the proposed price was higher than the monthly price for patients aged 12 and over. *JM*

Driven to innovate

FRED



Experience the integrated solution suite for smarter pharmacy operations.

PHARMACY CONNECT

STAND 56 - 57

YOU LEASE TIME, NOT SPACE

Still Waiting? The Landlord Isn't

Leverage **free access** to tools and resources for your lease.

Lease+

Click anywhere to get started!

Lease+.au

Dispensary Corner

LIKE matcha and miso, the Japanese fermented bean dish natto is making waves in the western world, due to the nutritional benefits it provides.

The dish is traditionally made by soaking soybeans in water, boiling or steaming it, and blending it with bacteria to ferment them.

Natto's key benefit is that it's very rich in nutrients including calcium, potassium, iron, manganese and vitamins K2, B6 and E, along with a standard 50g serve containing 10g of protein and 110 calories.

As a result, the dish is ideal for bone health, blood flow, skin elasticity, and surprisingly enough, strong oral health.

This is a common trend among fermented foods, known to create and fuel healthy bacteria for the gut and manage high blood pressure.

However, consumers must be able to stand natto's foul "ammonia-like" smell, as well as its sticky texture.

TWC unveils Clinical Faculty



TERRYWHITE Chemmart (TWC) has announced the launch of a National Clinical Faculty to support the next generation of pharmacists.

Led by deputy chief pharmacist Kate Gunthorpe, the faculty will provide pharmacists with ongoing mentorship and support via workshops, case-based learning, prescriber roundtables and more.

The initiative builds on TerryWhite Chemmart's Pathway to Prescribing program, which supports pharmacists transition from education to prescribing practice.

The inaugural Clinical Faculty consists of seven experienced pharmacist practitioners from across the TWC network, including Molly McGuire, Aarefa Husain, David Went, James Buckley, Amy Smith,

Shaun Tarrant, and Nick Pincombe.

Gunthorpe said the faculty "gives pharmacists the opportunity to continue learning from experienced peers, work through real clinical cases and access practical mentorship as they embed prescribing into everyday practice".

"Having access to experienced pharmacist practitioners who understand the realities of implementation and can provide practical advice makes an enormous difference to successful adoption," she added.

"Through the Clinical Faculty, we're developing a strong network of educators, mentors and clinical leaders who can help build capability across the profession for years to come." *JM*

Full disclosure

THE Thoracic Society of Australia and New Zealand (TSANZ) has called for pharmaceutical companies to disclose whether they have any financial or business connections to the tobacco, vaping or nicotine industries when they apply to have a medicine listed on the PBS.

Under the TSANZ's proposal, companies applying for PBS listing would be required to submit a declaration disclosing any actual, potential, or perceived tobacco, vaping and nicotine products industry interests across their corporate group and supply chains, along with the steps taken to identify and address those risks.

The proposal suggested that declarations would be published alongside existing PBS documentation, recorded on a public register and periodically audited.

According to TSANZ president, Professor Natasha Smallwood, the reform would help protect confidence in the systems behind publicly funded medicines.

"Australians have the right to know when the money spent on publicly funded medicines ultimately benefits the tobacco, vaping and nicotine products industry.

"We are not asking for any medicine to be banned or restricting patients' access to treatment," Smallwood said.

"We are asking companies to disclose if the tobacco, vaping and nicotine products industry benefits from public money."

See the full proposal, *A Clean Supply Chain for Publicly Funded Medicines*, [HERE](#).

Boost your CPD

PHARMACISTS can gain accredited Continuing Professional Development (CPD) points at Pharmacy Connect, which is now only two weeks away.

With clinical, business and plenary streams, as well as interactive pre-conference workshops, attendees can tailor their learning experience to suit their needs - info [HERE](#).

Nominate now for Dr Sainsbury Awards

NOMINATIONS are closing soon for the Australian Pharmacy Council's (APC) 2026 Dr Erica Sainsbury Awards, which recognise the pharmacists who go above and beyond to mentor the next generation.

The Early Career Pharmacy Educator Award, which acknowledges an individual who demonstrates innovation and passion in teaching, is open to self-nomination.

Meanwhile the Pharmacist Supervisor Award celebrates pharmacists who display the skills considered invaluable in the training of pharmacy interns and learners, and is open by nomination only.

The APC has encouraged pharmacists, educators, interns and employers to share this opportunity across their networks - applications and nominations are open [HERE](#) until 31 Aug.